Speakers

Co-Chairs

Dr. Leslie Fischer

Principal Patent Attorney
Sandoz (Princeton, NJ)

Co-Chairs Opening Remarks

July 21, 2021 • 10:00 am

Duane Marks

Assistant General Patent Counsel
Eli Lilly and Company

Written Description and Enablement in Antibody Patent Claims: International Perspectives on Establishing the Scope of Antibody Claims and Incorporating the Latest Developments into Your Patent Prosecution Strategy

July 21, 2021 • 4:15 pm

Speakers

Poopak (Paki) Banky

IP Litigation Counsel
Novartis

Life Sciences Litigator Think Tank: “What I Wish the Patent Prosecutor Would Have Done”

July 21, 2021 • 5:00 pm

Adrian Bradley

Partner
Cleveland Scott York (Thames Valley Reading, UK)

Exploring Effective Strategies for Obtaining Method of Treatment/Second Medical Use Patents, Personalized Medicine Patents and Dosage Regimen Patents

July 22, 2021 • 1:15 pm

Cara Coburn

Associate General Counsel, Patent Law
Genentech

Determining the Future Landscape of §101: Will We Ever Have Clarity on Patent Subject Matter Eligibility?

July 21, 2021 • 3:00 pm

Jim Czaban

Partner
Loeb & Loeb LLP

Evaluating the Consequence of a Skinny Label: Implications of GSK v. Teva

July 22, 2021 • 2:15 pm

Tina Dorr, Ph.D.

Partner
Cantor Colburn LLP

Navigating the Current Obviousness Landscape: Integrating the Latest Developments in Obviousness-Type Double Patenting and Inherency into Your Patent Prosecution Approach

July 22, 2021 • 3:30 pm

Andrew Faile

Acting Commissioner for Patents
U.S. Patent and Trademark Office (USPTO)

Keynote Address:

July 21, 2021 • 12:15 pm

Kathleen Kahler Fonda

Senior Legal Advisor, Office of Patent Legal Administration
U.S. Patent and Trademark Office (USPTO)

Navigating the Current Obviousness Landscape: Integrating the Latest Developments in Obviousness-Type Double Patenting and Inherency into Your Patent Prosecution Approach

July 22, 2021 • 3:30 pm

Wanda French-Brown

Partner
Loeb & Loeb LLP

Examining the Recent Resurgence of Doctrine of Equivalents: Weighing the Effects of the Latest DoE Decisions on Patent Prosecution and Litigation Strategies in the U.S., Europe and Asia

July 22, 2021 • 10:15 am

James M. Gould

Counsel
RatnerPrestia

Evaluating the Consequence of a Skinny Label: Implications of GSK v. Teva

July 22, 2021 • 2:15 pm

Felicity E. Groth

Partner
BakerHostetler

Exploring Effective Strategies for Obtaining Method of Treatment/Second Medical Use Patents, Personalized Medicine Patents and Dosage Regimen Patents

July 22, 2021 • 1:15 pm

Siegmund (“Sige”) Gutman

Partner
Chair, Life Sciences Patent Practice
Proskauer Rose LLP

Life Sciences Litigator Think Tank: “What I Wish the Patent Prosecutor Would Have Done”

July 21, 2021 • 5:00 pm

Sarah Hooson

Counsel, Patents
Merck

Evaluating the Consequence of a Skinny Label: Implications of GSK v. Teva

July 22, 2021 • 2:15 pm

Dr. Sebastian Höpfner

Partner
German and European Patent and Trademark Attorney
Bird & Bird (Munich, Germany)

Written Description and Enablement in Antibody Patent Claims: International Perspectives on Establishing the Scope of Antibody Claims and Incorporating the Latest Developments into Your Patent Prosecution Strategy

July 21, 2021 • 4:15 pm

Charlotte Jacobsen

Partner
Ropes & Gray LLP

Patent Term Extension Developments in the U.S. and Europe: Examining the Implications of Biogen v. Banner and Deciphering Europe’s SVC Manufacturing Waiver

July 22, 2021 • 11:30 am

Jenny Papatolis Johnson

Intellectual Property Executive Director
Endo Pharmaceuticals

Exploring Effective Strategies for Obtaining Method of Treatment/Second Medical Use Patents, Personalized Medicine Patents and Dosage Regimen Patents

July 22, 2021 • 1:15 pm

Thomas J. Kowalski

Partner
Duane Morris LLP

Determining the Future Landscape of §101: Will We Ever Have Clarity on Patent Subject Matter Eligibility?

July 21, 2021 • 3:00 pm

John D. Livingstone

Partner
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP (Atlanta, GA)

Examining the Recent Resurgence of Doctrine of Equivalents: Weighing the Effects of the Latest DoE Decisions on Patent Prosecution and Litigation Strategies in the U.S., Europe and Asia

July 22, 2021 • 10:15 am

Mythili Markowski

Senior Patent Attorney
Novartis

Redefining Your Global Patent Prosecution Strategy for 2021: Addressing the Top Challenges Companies are Currently Facing in Securing Patent Ownership in the U.S., Europe and China

July 21, 2021 • 10:15 am

Catherine McCarty

Partner
Goodwin Procter LLP

Redefining Your Global Patent Prosecution Strategy for 2021: Addressing the Top Challenges Companies are Currently Facing in Securing Patent Ownership in the U.S., Europe and China

July 21, 2021 • 10:15 am

Donna Meuth

Associate General Counsel, Intellectual Property
Eisai

Determining the Future Landscape of §101: Will We Ever Have Clarity on Patent Subject Matter Eligibility?

July 21, 2021 • 3:00 pm

Rachel Mumby

Partner
Bristows LLP (London, UK)

Patent Term Extension Developments in the U.S. and Europe: Examining the Implications of Biogen v. Banner and Deciphering Europe’s SVC Manufacturing Waiver

July 22, 2021 • 11:30 am

Amir Naini

Senior Counsel
Proskauer Rose LLP

Determining the Future Landscape of §101: Will We Ever Have Clarity on Patent Subject Matter Eligibility?

July 21, 2021 • 3:00 pm

Katie Nolan-Stevaux

Assistant General Counsel, Litigation
Genentech

Life Sciences Litigator Think Tank: “What I Wish the Patent Prosecutor Would Have Done”

July 21, 2021 • 5:00 pm

Kevin Noonan

Partner
McDonnell Boehnen Hulbert & Berghoff LLP

Gauging the Continued Impact of the Novel Coronavirus Across the Global IP Market: Compulsory Licensing and March-In Rights in the Age of COVID-19

July 21, 2021 • 11:15 am

Brendan M. O’Malley

Vice President, Head of Legal & IP
Corporate Secretary
Abeona Therapeutics Inc.

PTAB Year in Review: Examining the Latest PTAB Developments Impacting Patent Prosecution and Litigation, Key Federal Circuit Cases Involving the PTAB in the Last Year and an Update on Arthrex

July 21, 2021 • 12:45 pm

Bert Oosting

Partner
Hogan Lovells International LLP (Amsterdam, NE)

Redefining Your Global Patent Prosecution Strategy for 2021: Addressing the Top Challenges Companies are Currently Facing in Securing Patent Ownership in the U.S., Europe and China

July 21, 2021 • 10:15 am

Guido Pontremoli

Guido Pontremoli, Ph.D.

Global IP Head
Corp. Intellectual Property-Patents
Chiesi Farmaceutici S.p.A (Parma, Italy)

Examining the Recent Resurgence of Doctrine of Equivalents: Weighing the Effects of the Latest DoE Decisions on Patent Prosecution and Litigation Strategies in the U.S., Europe and Asia

July 22, 2021 • 10:15 am

Filko Prugo

Partner
Chair, Life Sciences IP Litigation
Ropes & Gray LLP

Life Sciences Litigator Think Tank: “What I Wish the Patent Prosecutor Would Have Done”

July 21, 2021 • 5:00 pm

Meaghan Richmond

Assistant General Counsel
AstraZeneca

Gauging the Continued Impact of the Novel Coronavirus Across the Global IP Market: Compulsory Licensing and March-In Rights in the Age of COVID-19

July 21, 2021 • 11:15 am

Kristel Schorr

Partner
Foley & Lardner LLP

Written Description and Enablement in Antibody Patent Claims: International Perspectives on Establishing the Scope of Antibody Claims and Incorporating the Latest Developments into Your Patent Prosecution Strategy

July 21, 2021 • 4:15 pm

Sharon Walker, Ph.D.

Director Legal
Translate Bio

Examining the Recent Resurgence of Doctrine of Equivalents: Weighing the Effects of the Latest DoE Decisions on Patent Prosecution and Litigation Strategies in the U.S., Europe and Asia

July 22, 2021 • 10:15 am

Laura Wine

Associate General Counsel, Intellectual Property
Arena Pharmaceuticals, Inc.

Navigating the Current Obviousness Landscape: Integrating the Latest Developments in Obviousness-Type Double Patenting and Inherency into Your Patent Prosecution Approach

July 22, 2021 • 3:30 pm